Shandong Beikede Bio Secures Tens of Millions RMB in Series Angel Funding Led by Partner Capital
Recently, the internationally leadingNano-grade Chitosan Oligosaccharide ProductsR&D, Production, and Sales SupplierShandong Beikede Sugar Biotechnology Co., Ltd. (hereinafter referred to as “Beikede Bio”)Announced the completion of a RMB 10 million angel round of financing, led byPartner CapitalLead investor. The funds from this round of financing will be primarily used for the company's product R&D investment, ensuringRegistration for functional testing and evaluation of health foods, while accelerating market channel promotion to expand the application of the company's products in the terminal market.
Beikede Biotechnology was established in January 2020. Led by Professor Yang Xin and Professor Wang Jing, both recognized as Taishan Industry Leading Talents of Shandong Province, the company leverages the Food Nutrition and Safety Innovation Team from the School of Medicine and Health at Harbin Institute of Technology. With over two years of dedicated expertise in chitosan oligosaccharide development grounded in glycobiology—the third milestone in life sciences—Beikede Biotechnology is a high-tech enterprise integrating industry, academia, and research, possessing internationally leading chitosan oligosaccharide preparation technologies. Chitooligosaccharides are prepared from raw materials such as shrimp and crab shells, and their bioactivity varies with molecular weight. As the applications of chitooligosaccharides become increasingly widespread, particularly in the fields of food, pharmaceuticals, cosmetics, animal feed, and aquaculture, the potential market size is enormous. Beikede Biotechnology focuses on the high-end chitooligosaccharide industry chain, with its R&D efforts primarily directed toward three key areas: functional health foods, biopharmaceuticals, and medical devices. The functions of chitooligosaccharides mainly include enhancing human immunity, inhibiting cancer cell activity, anti-inflammatory effects, lowering uric acid, reducing blood lipids, lowering blood glucose, protecting the liver and aiding alcohol metabolism, promoting bone injury repair, and regulating gastrointestinal function. Driven by market demand, the production of chitosan, the upstream product of chito-oligosaccharides, has been continuously increasing. In 2021, China's chitosan output reached 1,812.6 tons, a year-on-year increase of 7.5%. Benefiting from ample raw material supply, China's chito-oligosaccharide industry has achieved rapid development. Beicode BiologyOvercame technical challenges in the preparation of bioactive chitooligosaccharides, successfully developing nano-scale chitooligosaccharide products with high water solubility and potent biological activity; this technology is currently at an internationally leading level.。It addresses common industry pain points, including high molecular weight, poor water solubility, inconsistent quality, unstable functional activity, and insufficiently pronounced bioactive effects. For years, the R&D team has beenCircum-Nano-scale Chitosan Oligosaccharide ProductsTechPublished over 30 academic papers, with more than 20 indexed by SCI; one paper was selected as an ESI Hot Paper. Formulated one group standard and obtained six granted or pending patents. The project has received support from the Ministry of Science and Technology’s Agricultural Achievement Transformation Fund, the National Natural Science Foundation of China, the China Postdoctoral Science Foundation, the Heilongjiang Provincial Natural Science Foundation, and major projects funded by the Department of Education, with a cumulative R&D investment of over 20 million yuan. Fourteen postdoctoral fellows, doctoral candidates, and master’s students have been trained in research related to this technology. Beikede Biotechnology’s future product pipeline includes: leveraging the bioactive properties of chitooligosaccharides, such as immune enhancement and antibacterial effects, to develop biopharmaceuticals for postoperative recovery and adjuvant radiotherapy and chemotherapy; utilizing the amino group characteristics of chitooligosaccharides to create health supplements that improve gastrointestinal function, combat osteoarthritis, assist in lowering blood glucose, help regulate blood lipids and blood pressure, protect the liver, provide radioprotection, and prevent Alzheimer’s disease; and harnessing the moisture-absorbing, moisturizing, and antibacterial properties of chitosan to develop injectable gels, hydrating facial masks, antibacterial skincare products, and toothpaste that inhibits Helicobacter pylori.
About Partner Capital
Partner Capital, founded in 2003, is a leading comprehensive capital advisory services group in China, dedicated to providing high-growth enterprises with one-stop solutions for private equity financing, mergers and acquisitions and restructuring, IPO financial advisory, and private equity investment.
Partner Capital facilitates the rapid growth of high-potential enterprises through industry consolidation, acting as a capital advisor. It also engages directly within these companies to assist entrepreneurs in refining their business models, planning private equity financing and IPOs, executing mergers and acquisitions and restructuring, enhancing competitiveness, and integrating business resources. By providing end-to-end capital operation services, Partner Capital ultimately helps enterprises achieve successful IPOs and realize capital appreciation for entrepreneurs.